Carlos Barcenas
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Use of glucagon-like peptide-1 receptor agonists (GLP1-RA) for weight loss is increasing; implications in breast cancer (BC) survivors remain unclear.This retrospective cohort study evaluated treatment patterns, weight loss, and outcomes in BC survivors at an academic institution receiving GLP1-RA. We evaluated patients with non-metastatic (ductal carcinoma in situ (DCIS), stage 1-3) BC who received GLP1-RA (2005 – 2024). Linear regression models estimated associations between weight change and clinical factors. After excluding DCIS, propensity score matching (1:2) was used to match patients who received GLP1-RA with patients who did not, based on confounding covariates. Kaplan-Meier estimates and log-rank tests compared disease-free survival (DFS) and overall survival (OS) between GLP1-RA users versus non-users in the subgroup with invasive disease. We identified 1,022 patients; 79% had DM2. Median weight and body mass index at GLP1-RA initiation were 86.8 kg (47.2-175.0 kg) and 33.5 kg/m2 (18.9-61.8 kg/m2). In semaglutide or tirzepatide users (442, 43.2%), median weight change at 3, 6, and 12 months after GLP1-RA initiation was −1.9% (−13.2%-14.9%), −3.1% (−20.2%-19.0%), and −2.6% (−27.8%-11.5%), respectively. Endocrine therapy and metformin use were associated with weight gain and loss, respectively; invasive disease stage was linked to greater weight loss. GLP1-RA was not associated with DFS, but OS significantly differed between GLP1-RA users (n=810) and non-users (n=1620) (HR 0.37, 95% CI: 0.27-0.53, p<0.0001). In conclusion, in this real-world study in BC survivors, GLP1-RA was associated with modest weight loss and improved all-cause survival. Clinical trials are warranted to study GLP1-RA in this population.
Year:
2026
Year:
2026
The hormone receptor (HR)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC) cases. HR‐positive/HER2‐negative MBC is characterized by a relatively prolonged, although variable, disease course and substantial intertumoral and intratumoral heterogeneity. Although endocrine‐based therapies remain the cornerstone of treatment, nearly all patients eventually develop resistance, which is increasingly addressed with biologically targeted agents and newer‐generation cytotoxic drugs. This review summarizes the current understanding of HR‐positive/HER2‐negative MBC biology, highlighting mechanisms of intrinsic and acquired resistance, including driver genomic alterations that, along with clinical factors, help guide therapeutic choices and sequencing. The authors specify and discuss how genomic and transcriptomic profiling inform treatment selection and how side effects and overall patient experience are considered in decision making. Advances in targeted therapies, such as CDK4/6 (cyclin‐dependent kinase 4/6), PI3K (phosphatidylinositol 3‐kinase), and AKT (protein kinase B) inhibitors, and next‐generation estrogen receptor degraders are reviewed along with the expanding role of antibody–drug conjugates and biomarker‐guided tumor‐agnostic biologic therapies. The authors also explore evolving biologic concepts, including the impact of the tumor microenvironment on resistance and disease progression, and consider the distinct clinical behavior of invasive lobular carcinoma and current approaches. Emerging data from contemporary clinical trials promise to refine clinical and biomarker‐driven algorithms and improve outcomes for patients with HR‐positive/HER2‐negative MBC. Ongoing multi‐omic research and adaptive clinical strategies will be essential to further the application of precision oncology in this most common subtype of MBC. Importantly, patient‐reported outcomes, shared decision making, and real‐world evidence are increasingly useful in formulating comprehensive care plans, guidelines, and policy. The modern treatment landscape features a personalized approach that integrates clinical features, biomarkers, and patient preferences across the disease continuum.
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Background/Objectives: The increasing prevalence of obesity has led to a growing interest in anti-obesity medications (AOMs). While these medications have shown promise in aiding weight loss, their potential impact on reducing obesity-related cancers (ORCs) incidence remains poorly understood, particularly among women over 65 years of age. This study examined the association between the use of AOMs and the risk of ORCs in this population. Methods: A retrospective cohort study was conducted using 2007–2015 SEER-Medicare data, including 10,830 women aged ≥65 years in a 1:2 propensity-score matching design. The primary exposure was AOM use, with additional analyses focused specifically on phentermine and liraglutide exposure. Conditional multivariable Cox proportional hazards models were conducted. Results: We found an inverse association between the use of AOMs and the risk of ORCs (aHR: 0.78; 95% CI: 0.73–0.84; p < 0.001). Similar findings were observed in cancer-specific sites analysis, advanced-stage ORCs (aHR: 0.76; 95% CI: 0.65–0.89; p < 0.001), breast (aHR: 0.84; 95% CI: 0.77–0.91; p < 0.001), colorectal (aHR: 0.82; 95% CI: 0.71–0.96; p = 0.010), and advanced-stage colorectal cancers (aHR: 0.71; 95% CI: 0.54–0.91; p < 0.001). In secondary analyses, phentermine was inversely associated with the risk of ORCs, breast, and endometrial cancers, but no associations with liraglutide were observed. Conclusions: The use of AOMs, including phentermine, was inversely associated with ORCs and some cancer-specific sites in a cohort of older women. Further prospective studies are warranted to validate these findings among women of different age groups and to identify the underlying biological mechanisms.
Year:
2025
Rosai-Dorfman disease is a non-Langerhans cell histiocytosis with ubiquitous distribution. Although more common in lymph nodes, it has been described in many organ systems. The current case depicts a 54-year-old woman with a history of estrogen receptor-positive breast carcinoma who showed different image features of metastatic lymph nodes and splenic Rosai-Dorfman disease on FDG and FES PET/CT scans.
Year:
2025
Background Cancer is a life-threatening, stressful event, particularly for young adults due to delays and disruptions in their developmental transitions. Cancer treatment can also cause adverse long-term effects, chronic conditions, psychological issues, and decreased quality of life (QoL) among young adults. Despite numerous health benefits of health behaviors (eg, physical activity, healthy eating, no smoking, no alcohol use, and quality sleep), young adult cancer survivors report poor health behavior profiles. Determining the associations of stress (either cancer-specific or day-to-day stress), health behaviors, and QoL as young adult survivors transition to survivorship is key to understanding and enhancing these survivors’ health. It is also crucial to note that the effects of stress on health behaviors and QoL may manifest on a shorter time scale (eg, daily within-person level). Moreover, given that stress spills over into romantic relationships, it is important to identify the role of spouses or partners (hereafter partners) in these survivors’ health behaviors and QoL. Objective This study aims to investigate associations between stress, health behaviors, and QoL at both within- and between-person levels during the transition to survivorship in young adult cancer survivors and their partners, to identify the extent to which young adult survivors’ and their partners’ stress facilitates or hinders their own and each other’s health behaviors and QoL. Methods We aim to enroll 150 young adults (aged 25-39 years at the time of cancer diagnosis) who have recently completed cancer treatment, along with their partners. We will conduct a prospective longitudinal study using a measurement burst design. Participants (ie, survivors and their partners) will complete a daily web-based survey for 7 consecutive days (a “burst”) 9 times over 2 years, with the bursts spaced 3 months apart. Participants will self-report their stress, health behaviors, and QoL. Additionally, participants will be asked to wear an accelerometer to assess their physical activity and sleep during the burst period. Finally, dietary intake (24-hour diet recalls) will be assessed during each burst via telephone by research staff. Results Participant enrollment began in January 2022. Recruitment and data collection are expected to conclude by December 2024 and December 2026, respectively. Conclusions To the best of our knowledge, this will be the first study that determines the interdependence of health behaviors and QoL of young adult cancer survivors and their partners at both within- and between-person levels. This study is unique in its focus on the transition to cancer survivorship and its use of a measurement burst design. Results will guide the creation of a developmentally appropriate dyadic psychosocial or behavioral intervention that improves both young adult survivors’ and their partners’ health behaviors and QoL and potentially their physical health. International Registered Report Identifier (IRRID) DERR1-10.2196/53307
Year:
2024
Year:
2023
Collaborators (14)
Karen Basen-Engquist
The University of Texas MD Anderson Cancer Center
sairah ahmed
Professor
The University of Texas MD Anderson Cancer Center
Jaime Almandoz
Associate Professor and Medical Director of Weight Wellness Program
University of Texas Southwestern Medical Center
Kristofer Jennings
Assistant Professor
The University of Texas MD Anderson Cancer Center
Mariana Chavez Mac Gregor
Professor
The University of Texas MD Anderson Cancer Center
Yisheng LI
Professor
The University of Texas MD Anderson Cancer Center
Amil Shah
Professor of Medicine, Director of Population Sciences
University of Texas Southwestern Medical Center
David S. Lopez
Associate Professor of Epidemiology
University of Texas Medical School at Houston
Kelseanna Hollis-Hansen
Research Assistant Professor
University of Texas Southwestern Medical Center
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Jasmine Sukumar
The University of Texas MD Anderson Cancer Center
Suzanne Fuqua
Professor
Baylor College of Medicine
Michael Roth
Associate Professor of Pediatrics
The University of Texas MD Anderson Cancer Center Children's Cancer Hospital
Senthil Damodaran
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.